<DOC>
	<DOCNO>NCT00396435</DOCNO>
	<brief_summary>The purpose study evaluate , renal transplant patient CGD , effect two level haemoglobin quality life 6 month speed progression renal function degradation 24 month . This study recruit 140 patient 21 center France .</brief_summary>
	<brief_title>Correction Anaemia Progression Renal Failure Transplanted Patients</brief_title>
	<detailed_description>The number patient arrive year stage final renal insufficiency ( IRT ) require dialysis substitution cease grow , parallel continuous age population industrialized country . The incidence IRT approximately 110 new patient per million inhabitant per year , represent annual progression approximately 4 % 8 % accord areas.Approximately 35000 patient currently treat dialysis , 90 % hemodialysis 10 % per peritoneal dialysis . The alternative treatment IRT renal transplantation . Approximately 2000 patient transplanted year France , estimate minimum 3000 transplantation annually carry order answer request patient register chronic program dialysis transplant age . The total number patient live functional graft approximately 15000 . The IRT major problem public health cost considerable : le 50000 patient , one represent nearly 4 % annual budget social security . To slow progression IRC represent major therapeutic challenge , include transplanted patient . The physiopathological mechanism propose explain harmful role anaemia progression renal lesion IRC rest tissue hypoxia induce reduction haemoglobin . The tissue hypoxia support development interstitial fibrosis stimulate production type I collagen inhibitor metalloproteases , imply extracellular matrix degradation . The hypoxia also stimulate synthesis TGF-beta , pro-fibrosing factor imply progression many renal disease , particular nephropathy diabetic . By reduce hypoxia thanks correction anaemia EPO , one hope slow progression interstitial fibrosis , thus progression renal insufficiency . Lastly , correction anaemia reduces resistance insulin secondary hyperinsulinism uraemia , improve dyslipidemia oxidize stress , factor also imply progression many nephropathy , diabetic . It appear anaemia factor risk progression chronic nephropathy . To slow progression chronic dysfunction graft important challenge shortage graft impossibility , current state French center renal transplantation carry number necessary graft provide current wait list . Our hypothesis , check , make possible appreciably improve quality life transplant patient slow progression IRC , thus delay duration return dialysis . Population : Renal patient transplant since least 12 month , present CGD define 20 ml/mn/1,73 m2 &gt; Clcr &lt; 50 ml/mn/1,73 m2 anaemia ( Hb &lt; 11,5 g/dl ) The patient answer criterion selection assign randomization one two follow group : - Group : target haemoglobin : 13 15 g/dl - Group b : target haemoglobin : 10,5 11,5 g/dl Criteria inclusion - Adults male female sex 18 year - Patients profit one 1st one 2nd renal Transplantation - Patients Transplanted since 1 year - Patients CGD define Clcr &lt; 50 ml/mn/1,73 m2 - Patients present anaemia : Hb low 11,5 g/dl - Absence deficiency iron - Patients give write consent Study Treatment : Neorecormon® ( Epoétine beta ) cutaneous injection The objective study show difference group A `` haemoglobin target : 13 15 g/dl '' group B `` haemoglobin target : 10,5 11,5 g/dl '' , regard renal function . The calculation number patient thus base model covariance analysis repeat measurement clearance creatinin whole time evaluate J0 M24 follow hypothesis : - H0 : effect group two year follow-up - H1 : Effect group , evolution different value Clcr follow-up The alfa-risk ( probability reject H0 wrongly ) fix 5 % The beta-risk ( probability keep H0 wrongly ) 10 % The total number patient randomize estimate 140 ( 70 group ) This number patient also make possible test score quality life power high 90 %</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Adults male female 18 year male female sex 70 year Patients profit one 1st one 2nd transplantation Patients transplant since 1 year less 20 year . Patients CDG define clearance creatinin , low 50 ml/mn/1,73 m2 ( accord Gault Cockcroft ) whose renal function stable last 3 month ( variation Scr le 20 % last 3 month ) Patients present anaemia : Hb low 11.5 g/dl No deficiency iron : Saturation transferrin &gt; 20 % ironnemia &gt; 50 mg/l time screen visit Patients give write consent Major form drepanocytosis thalassaemia Iron Deficit ( CST &lt; 20 % ferritin &lt; 50 mg/l ) Haemolysis ( haptoglobin &lt; 0,30 g/l ) Severe renal insufficiency : Clcr &lt; 20 ml/min/1,73 m2 Severe Hyperparathyroidy ( serum PTH &gt; 800 pg/ml ) Evolutionary chronic inflammatory Disease ( CRP &gt; 15 mg/l ) Acute chronic infectious disease Evolutionary neoplasic Disease Infection HIV viral cirrhosis Recent Antecedents MI AIT ( &lt; 3 month ) Severe Arteritis low limb ( Stage III IV ) Acute Rejection require treatment 3 previous month Blood Transfusion last 3 month Evolutionary GI Ulcer last 3 month Severe Arterial HyperTension control medicamentous treatment ( NOT &gt; 170 mm Hg PAD &gt; 100 mm Hg treatment ) Epilepsy recent diagnosis Relevant biological value ( screen visit ) : Proteinuria &gt; 3 g/24h Serum Albumin &lt; 30 g/l Platelets &gt; 600.000/µl Programmed heavy surgery Pregnancy breast feed Administration experimental drug 30 day precede screening visit Known Oversensitiveness Epoetin beta Patients Sirolimus Patients EPO screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>anaemia</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>kidney failure</keyword>
</DOC>